Pharma Report on Malignant Mesothelioma – Pipeline Review, H2 2020


Malignant Mesothelioma – Pipeline Review, H2 2020


Malignant Mesothelioma – Pipeline Review, H2 2020, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights

Malignant Mesothelioma – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 8, 46, 42, 1, 29, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 7 and 8 molecules, respectively.

Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).
– The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
AbbVie Inc
ADCendo ApS
Agios Pharmaceuticals Inc
Akeso Inc
Aldeyra Therapeutics Inc
Almac Discovery Ltd
Amphera BV
AnGes Inc
Apollomics Inc
Applied Research using OMIC Sciences SL
Arch Oncology Inc
Argenx SE
Ascentage Pharma Group International
AstraZeneca Plc
Atara Biotherapeutics Inc
Aurigene Discovery Technologies Ltd
Bao Kang Biomedical Healthcare Inc
Bayer AG
BerGenBio ASA
Biogen Inc
Bionomics Ltd
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Calithera Biosciences Inc
CanBas Co Ltd
Canget BioTekpharma LLC
Checkpoint Therapeutics Inc
Chiome Bioscience Inc
Clovis Oncology Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Deciphera Pharmaceuticals Inc
Delta-Fly Pharma Inc
Eisai Co Ltd
Eli Lilly and Co
EnGeneIC Ltd
Epigene Therapeutics Inc
Epizyme Inc
Eureka Therapeutics Inc
F. Hoffmann-La Roche Ltd
FKD Therapies Oy
Flag Therapeutics Inc
Genelux Corp
GlaxoSmithKline Plc
H2Biologics Inc
Harpoon Therapeutics Inc
Hebei Senlang Biotechnology Inc Ltd
Horizon Therapeutics Plc
Hutchison MediPharma Ltd
IDAC Theranostics Inc
Ikena Oncology Inc
Incyte Corp
Infinity Pharmaceuticals Inc
Inhibrx Inc
Invion Ltd
iOnctura SA
Juno Therapeutics Inc
Karyopharm Therapeutics Inc
Kiromic BioPharma Inc
Kyowa Kirin Co Ltd
L.E.A.F. Pharmaceuticals LLC
Laboratoires Pierre Fabre SA
Lipac Oncology LLC
LipoSeuticals Inc
MacroGenics Inc
Marino Biotechnology Co Ltd
MaxCyte Inc
MELEMA Pharma GmbH
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Minneamrita Therapeutics LLC
Molecular Partners AG
MolMed SpA
Momotaro-Gene Inc
MTG Biotherapeutics Inc
NeoTX Therapeutics Ltd
Novartis AG
Oasmia Pharmaceutical AB
Oncology Venture A/S
Oncovir Inc
Ono Pharmaceutical Co Ltd
OSE Immunotherapeutics
Pharma Mar SA
PlumeStars Srl
Polaris Pharmaceuticals Inc
Quadriga BioSciences Inc
Seattle Genetics Inc
SELLAS Life Sciences Group Inc
Shanghai GeneChem Co Ltd
Shanghai Keqi Pharmaceutical Technology Co Ltd
Shionogi & Co Ltd
Sotio AS
Sumitomo Dainippon Pharma Oncology, Inc
Targovax ASA
TCR2 Therapeutics Inc
TRACON Pharmaceuticals Inc
Ube Industries Ltd
Ultimovacs AS
VasGene Therapeutics Inc
Venus Remedies Ltd
Verastem Inc
VM Discovery Inc
Xencor Inc
Y’s Therapeutics Co Ltd
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd

For queries regarding this report:

Contact Us:
Ritesh Tiwari, Director
USA: +1-800-416-3124

Follow us on Social Media:

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: *Industry Press Release is a part of Research By Markets.